GSK plc with ticker (LON:GSK) now has a potential downside of -1.9% according to JP Morgan.
JP Morgan set a target price of 1,400 GBX for the company, which when compared to the GSK plc share price of 1,427 GBX at opening today (28/04/2023) indicates a potential downside of -1.9%. Trading has ranged between 1,281 (52 week low) and 3,408 (52 week high) with an average of 7,185,125 shares exchanging hands daily. The market capitalisation at the time of writing is £58,926,287,330.
GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio includes more than 20 vaccines that help protect people from a range of diseases and infections throughout their lives. Its specialty medicines include medicines for immune-mediated conditions, including the chronic autoimmune condition lupus, respiratory disease, and human immunodeficiency virus (HIV). Its general medicines include inhaled medicines for asthma and chronic obstructive pulmonary disease (COPD), antibiotics and medicines for skin diseases. It has a global network of about 12 vaccines manufacturing sites.
GSK plc -1.9% potential downside indicated by JP Morgan
- Written by: Charlotte Edwards
Find more news, interviews, share price & company profile here for:
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.
GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.
GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers.
GSK's ADC GSK5764227 gains FDA Breakthrough Therapy status for treating relapsed or refractory osteosarcoma, addressing critical unmet medical needs.
GSK's Nucala has been approved in China as an add-on treatment for CRSwNP, marking the first anti-IL-5 therapy for adults with this chronic condition.
